Blow-fill-seal (BFS) technology is fast rising to the top of the agenda as a promising container format for pharmaceutical and biotech companies developing sterile ophthalmic therapies.
This efficient manufacturing process sees plastic containers blow-formed, filled and sealed in a sterile environment. They are ideal for offering single doses of sterile drug products — not just ophthalmics, but also injectables and inhalation treatments — enhancing self-administration convenience while reducing the risk of product waste.
BFS unidose format offers unique benefits including:
No need for preservatives in unidose and less risk of microbial contamination as the container is sealed as soon as it is filled with formulation and contains only a single dose
Minimised risk of breakage, as it is made of plastic, not glass, reducing the need for secondary packaging, and cutting transport and storage costs
Production advantages using plastic instead of glass vials due to a lower risk of component supply shortages and it provides a faster, simpler, and cheaper process, and also has a lesser environmental impact
BFS is suitable for solutions, gels, suspensions and emulsions, and for even the most sensitive treatments, such as biologics, supporting stability through the use of temperature-controlled storage or nitrogen atmosphere filling.
But how can pharma and biotechs effectively harness BFS technology? What should companies bear in mind?
In this webinar, we will explore the numerous advantages BFS unidose format offer over multidose options for ocular applications, as well as over single-dose glass vials. We will dive into the aspects companies need to consider to utilise BFS in ophthalmic drug development and outline how Recipharm can support making the most of this technology.
Webinar Learning Objectives:
What is BFS technology and the unique benefits of unidose BFS for ophthalmics, biologics and other sterile drug products
What are the advatanges of BFS unidose format in comparison to ocular multidose or glass vial format?
How Recipharm can support companies in switching to unidose BFS
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
